For this reason, the arginine:ornithine ratio in patients’ samples was calculated to evaluate if this ratio could aid in differentiating individuals with arginase deficiency from those with pseudo‐hyperargininemia secondary to tPA administration and/or MELAS receiving IV arginine therapy (Table 1). This evidence concerns the gene PLAT and MELAS.